765 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RESPONSE (RPCDBDR) TRIAL OF CTS-1027, AN INHIBITOR OF MATRIX METALLOPROTEASES (MMPS) IN PATIENTS WITH HCV WHO HAD FAILED PRIOR THERAPIES Academic Article uri icon

publication date

  • January 1, 2010